Zepbound (tirzepatide), a GLP-1 receptor agonist developed by Eli Lilly, has emerged as a promising treatment for chronic weight management
The study included health records for 11,681 adults with Type 2 diabetes who had a moderate or high risk score as determined by the 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk score, a standardized cardiovascular disease calculator outlined in a 2018 special report from the American Heart Association and the American College of Cardiology
Our providers will review your medical history, health goals, and any current medications to ensure semaglutide or tirzepatide is a safe and effective choice for you
What to Expect from Semaglutide Treatment Semaglutide treatment typically initiates with the lowest practical dose, with gradual increments monitored by your provider to sustain consistent weight reduction
In fact, I almost always advise against intervertebral disc injections, as they often cause more harm than good over time